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Background: t-MDS/AML is the major cause of non-relapse mor-
tality after aHCT for hematologic malignancies. Independent con-
tributions by pre-aHCT therapeutic exposures and aHCT-related
factors (stem cell mobilization, conditioning) to t-MDS/AML risk
are unknown.
Methods: From 1986 to 2006, 2104 consecutive patients (median age:
49 yr) received aHCTforNHL(n5 1029),MM(n5 612), orHL (n5
463), atCity ofHope (COH). Information regarding t-MDS/AMLdi-
agnosiswasprocured frommedical records andCaliforniaCancerReg-
istry to ensure complete capture. A retrospective cohort design
described the cumulative incidence of t-MDS/AML. A nested case-
control design evaluated the role of pre-aHCT therapeutic exposures
and aHCT-related factors. Cases (t-MDS/AML post-aHCT) were
matched to controls (no t-MDS/AML post-aHCT) for primary diag-
nosis, age at aHCT, year of aHCT, and race/ethnicity.
Results: By 2008, 97 patients had developed t-MDS/AML (cumula-
tive incidence: 5.5% at 10 years [HL: 7.0%, NHL: 6.4%, MM:
2.4%]). Cohort study: multivariable analysis revealed the following
to be associated with t-MDS/AML risk: diagnosis of HL (RR 5
2.0, 95%CI, 1.2-3.5; ref grp: NHL), older age at aHCT (601 yr:
RR 5 4.7, 95%CI, 2.1-10.1; ref grp:\ 40 yr), use of PBSC (RR 5
4.7, 95%CI, 1.9-11.5; ref group: BM/BM1PBSC), and exposure
to TBI (RR 5 1.7, 95%CI, 1.0-2.9). Case-control study: multivari-
able analysis revealed pre-aHCT alkylating agent (high dose: OR
5 2.3, 95% CI, 1.2-4.3) and topoisomerase II inhibitor (high dose:
OR 5 2.1, 95% CI, 1.0-4.1), stem cell mobilization with etoposide
(OR 5 7.7, 95% CI,1.7-34.8) and conditioning with TBI (OR 5
4.0, 95% CI, 2.0-8.2) to be associated with t-MDS/AML risk.
Sub-analyses by cytogenetic abnormalities revealed pre-aHCT ex-
posure to alkylating agents (OR 5 2.7, 95%CI, 1.1-6.4) and TBI
(OR 5 4.1, 95%CI, 1.7-9.8) to be associated with increased risk of
alkylating-agent associated t-MDS/AML (5/7); and mobilization
with etoposide (OR 5 14.2, 95%CI, 1.0-192) and TBI (OR 5 9.9,
95%CI, 1.7-57) to be associated with topoisomerase inhibitor-asso-
ciated t-MDS/AML (11q23/21q22). Of the 97 t-MDS/AML pa-
tients, 76 have died (median survival: 10 months from t-MDS/
AML) by the end of 2009; overall survival was 22% at 5 years.
Conclusions:This large study with near-complete ascertainment of
cases, demonstrates the role of pre-aHCT therapeutic exposures, use
of etoposide for stem cell mobilization, and exposure to TBI to
collectively and independently increase the risk of t-MDS/AML.235
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HCT recipients are at risk for impaired fertility. Physician percep-
tions and practices can be a barrier to informing patients about fertility
preservation options.We conducted a survey ofHCTphysicians in the
United States to evaluate knowledge of fertility preservation and to de-
scribepracticebehaviors andbarriers to discussing fertilitypreservationwith HCT recipients of child-bearing age. Using CIBMTR email list,
1035 transplant physicians were invited by email to participate in a 29-
item web survey. Of these, 185 participants completed the survey (re-
sponse rate 18%). 69% and 31%of respondents weremale and female,
68%, 22%and 10% took care of adult, pediatric andboth adult and pe-
diatric patients, and 55% and 45% had graduated frommedical school
before and after 1990, respectively. 64% of respondents had access to
infertility specialist at their own center, 28% in another institution in
the community and 8% had no access to infertility specialist. 83% re-
spondents felt that patients were interested in learning about effects
of HCT on fertility. 80% always or often felt comfortable discussing
fertility preservation with their patients. 88% always or often discussed
the impact of HCT on fertility and 51% always or often discussed fer-
tility issueswithpatients evenwhenprognosiswaspoor.However, 48%
rarely or never provided their patientswith educationalmaterials about
fertility preservation. 30%always or often consulted and54%always or
often referred their patients to an infertility specialist. 40% were un-
aware of ASCO fertility preservation guidelines for cancer patients
and29%rarely orneverused these guidelines.Commonbarriers todis-
cussing fertility preservation with patients were: patient being too ill to
delay treatment (55%), insurance not covering fertility preservation
(35%), patients inability to afford fertility preservation (33%) and
time constraints (27%).On univariate analysis, access to infertility spe-
cialistwas associatedwithconsultationand referral practices for fertility
(Table 1). Our study highlights the variation in transplant physician
perceptions and practice behaviors regarding fertility preservation. Al-
though relatively low response rate is a limitation of our study, HCT
physicians in general are interested in discussing fertility issues with
their patients but lack educational materials. Informational materials
and guidelines on fertility preservation specifically targeted to HCT
physicians are needed.
Table 1. Characteristics of respondents who consult or refer
their patients to an infertility specialist
Always/ Rarely/
Physician Characteristics Often Sometimes Never P-value#Consult infertility specialist with questions about fertility issues
Gender
Male, N (%) 36 (31) 37 (32) 43 (37) 0.45
Female, N (%) 13 (25) 22 (42) 18 (34)
Practice type
Adult, N (%) 30 (27) 40 (35) 43 (38) 0.59
Pediatric, N (%)* 18 (34) 18 (34) 17 (32)
Access to specialist
In same institution, N (%) 39 (36) 37 (35) 31 (29) <.0001
In another institution, N (%) 10 (21) 21 (45) 16 (34)
No access, N (%) 0 0 13 (100)
Refer patients who have questions about fertility to an infertility
specialist
Gender
Male, N (%) 64 (55) 31 (27) 21 (18) 0.89
Female, N (%) 28 (53) 16 (30) 9 (17)
Practice type
Adult, N (%) 60 (53) 30 (27) 23 (20) 0.53
Pediatric, N (%)* 30 (57) 16 (30) 7 (13)
Access to specialist
In same institution, N (%) 63 (59) 32 (30) 12 (11) <.0001
In another institution, N (%) 29 (62) 12 (26) 6 (13)
No access, N (%) 0 2 (15) 11 (85)*Includes physicians who take care of both adult and pediatric patients
#Chi-square or Fisher’s test p-value, as appropriate236
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